glp-1 blood brain barrier Hunting for heroes: neurons mediating GLP-1R agonists in obesity treatment How GLP-1 drugs affect the

This week, the FDA officially removed Novo Nordisks popular weight-loss and diabetes medications, Wegovy and Ozempic , from its drug shortage list, indicating that supply now meets or exceeds U.S

Being a leader in microneedling TDDS, their unique micro needle technology, DEN (Droplet Extension Needle), allows them to transfer drugs through a soluble micro needle. Raphas has FDA cGMP manufacturing validation for microneedle skin patches and has completed Phase 1 clinical trials

Patients with multiple comorbidities, especially those with limited treatment options, are significantly more likely to initiate GLP1 therapy

Obviously we do have 20 years, as you said, although it was with lower doses with individuals with type 2 diabetes using that as a group to compare to we have not seen any development of concerns that have emerged